Centogene (NASDAQ:CNTG – Get Rating) was the target of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 18,700 shares, a decrease of 20.1% from the June 30th total of 23,400 shares. Approximately 0.3% of the company's shares are sold short. Based on an average daily volume of 9,600 shares, the short-interest ratio is currently 1.9 days.
Centogene Stock Performance
NASDAQ CNTG opened at $1.55 on Thursday. The company has a market capitalization of $30.78 million, a price-to-earnings ratio of -0.64 and a beta of -1.18. Centogene has a twelve month low of $1.34 and a twelve month high of $11.61. The stock has a fifty day simple moving average of $2.24 and a 200 day simple moving average of $3.30. The company has a quick ratio of 2.41, a current ratio of 2.48 and a debt-to-equity ratio of 0.67.
Get
Centogene alerts:
Centogene (NASDAQ:CNTG – Get Rating) last issued its quarterly earnings results on Friday, July 15th. The company reported ($0.54) earnings per share for the quarter. Centogene had a negative return on equity of 134.55% and a negative net margin of 35.35%. The business had revenue of $11.59 million for the quarter. Sell-side analysts expect that Centogene will post -1.72 EPS for the current year.
Institutional Trading of Centogene
An institutional investor recently bought a new position in Centogene stock. DekaBank Deutsche Girozentrale bought a new stake in Centogene (NASDAQ:CNTG – Get Rating) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 16,319 shares of the company's stock, valued at approximately $67,000. DekaBank Deutsche Girozentrale owned 0.08% of Centogene at the end of the most recent reporting period.
Analyst Ratings Changes
Separately, SVB Leerink decreased their price objective on Centogene from $10.00 to $6.00 and set an "outperform" rating for the company in a report on Monday, July 18th.
Centogene Company Profile
(Get Rating)
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing.
Read More
- Get a free copy of the StockNews.com research report on Centogene (CNTG)
- There Are Different Types of Stock To Invest In
- Is it Time to Tap Molson Coors or Will Beer Sales Turn Flat?
- Is Starbucks Shooting For The Moon?
- PayPal Continues To Struggle As Competition Increases
- Two High-Yield Deep-Values You Shouldn't Ignore
Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.
